Back

Effect of concomitant antiplatelet agents on clinical outcomes in the Edoxaban versus Warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomised trial

25 August 2018 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 1 - Atrial fibrillation - Stroke Prevention Cardioversion and Defibrillation ESC Premium Access ESC Congress 2018

About the speaker

Photo
Professor Andreas Goette

Saint Vincenz Hospital Paderborn, Paderborn (Germany)

8 More presentations in this session

Presentation thumbnail
Temporal relations between atrial fibrillation and ischemic stroke and their prognostic impact on mortality
Doctor S. Camen (Hamburg, DE)
Abstract
Presentation thumbnail
Predictors of stroke and overall mortality in real world patients with atrial fibrillation treated with oral anticoagulants.
Doctor M. Anguita Sanchez (Cordoba, ES)
Abstract
Presentation thumbnail
Clinical Efficacy and Safety of Standard-Dose and Low-Dose Non-Vitamin K Antagonist Oral Anticoagulants in Asian Patients with Non-Valvular Atrial Fibrillation: Results from a Nationwide Cohort Study
Doctor M. Cho (Seoul, KR)
Abstract
Presentation thumbnail
The global ETNA-AF registry programme: snapshot baseline demographics and patient characteristics from more than 17,700 atrial fibrillation patients on edoxaban
Doctor Y. Koretsune (Osaka, JP)
Abstract Slides
Presentation thumbnail
Effect of advanced age on plasma homocysteine levels and its association with ischemic stroke in non-valvular atrial fibrillation
Doctor Y. Yao (Beijing, CN)

Access the full session

Session thumbnail
Poster Session 1 - Atrial fibrillation - Stroke Prevention

The Event

Event poster

ESC Congress 2018

25 August - 29 August 2018

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources